Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD long-term extension in SLE
2023-505635-13-00Phase 3Authorised
- Sponsor
- Biogen
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Litifilimab with Placebo / dose-blind comparator (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs) and Number of serious adverse events (SAEs). Planned start Jul 2024; status: authorised.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-505635-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505635-13-00.